Comparative Pharmacology
Head-to-head clinical analysis: GYNOREST versus PROGESTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNOREST versus PROGESTERONE.
GYNOREST vs PROGESTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gynorest (dydrogesterone) is a synthetic progestogen that binds to the progesterone receptor with high selectivity, inducing conformational changes that promote transcription of progesterone-responsive genes. It has no androgenic, estrogenic, or corticosteroid activity, and does not inhibit ovulation.
Progesterone binds to progesterone receptors (PR-A and PR-B) in target tissues, modulating gene expression to induce secretory changes in the endometrium, support pregnancy, and regulate gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
100 mg orally twice daily for 5-10 days or 300 mg orally once daily for 6-12 days.
Oral: 200-400 mg daily in 1-2 divided doses; Intramuscular: 50-100 mg daily; Vaginal: 200-400 mg daily in 1-2 divided doses.
None Documented
None Documented
Clinical Note
moderateMedroxyprogesterone acetate + Digoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digoxin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Digitoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digitoxin
Terminal elimination half-life is approximately 16-20 hours; supports twice-daily dosing for maintenance of therapeutic levels.
Elimination half-life: approximately 5-15 minutes for intravenous progesterone; terminal half-life of metabolites (pregnanediol) is about 2-8 hours, but clinical effects (e.g., endometrial transformation) persist for days due to receptor-mediated activity.
Renal: 50-80% as metabolites; Fecal: 20-50% as metabolites; Biliary excretion contributes to fecal elimination.
Renal (50-60% as metabolites) and fecal (10-20%). Biliary excretion of metabolites occurs; enterohepatic recirculation may contribute to prolonged presence. Unchanged drug negligible in urine.
Category C
Category D/X
Progestin
Progestin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digitoxin."